CCR5Delta32 genotype is associated with outcome in type 2 diabetes mellitus

Friso L H Muntinghe; Sascha Gross; Stephan J L Bakker; Gijs W D Landman; Pim van der Harst; Henk J G Bilo; Gerjan Navis; Mike W Zuurman

doi:10.1016/j.diabres.2009.08.013

CCR5Delta32 genotype is associated with outcome in type 2 diabetes mellitus

Friso L H Muntinghe, Sascha Gross, Stephan J L Bakker, Gijs W D Landman, Pim van der Harst, Henk J G Bilo, Gerjan Navis, Mike W Zuurman

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

AIMS: To test whether the genetic variant CCR5Delta32 in the CC-chemokine receptor 5, which is known to lead to CCR5 deficiency, is associated with mortality in type 2 diabetes patients.

METHODS: We examined the effect of presence or absence of the CCR5Delta32 on overall and cardiovascular mortality risk in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) cohort, a type 2 diabetes patient cohort.

RESULTS: We studied 756 patients with a mean duration of follow-up of 5.4 (+/- 1.4) years. 194 patients died during follow up of which 83 were cardiovascular deaths. 144 subjects (19%) carried the CCR5Delta32 deletion. CCR5Delta32 carriers had an adjusted hazard ratio of 0.62 (95%CI: 0.40-0.96; p=0.03) for all-cause mortality and 0.63 (95%CI: 0.33-1.19; p=0.16) for cardiovascular mortality.

CONCLUSIONS: The presence of CCR5Delta32 is associated with better survival in type 2 diabetes patients. These data suggest that it is worthwhile to explore the protective potential of pharmacological blockade of CCR5 in type 2 diabetic patients.

Original language	English
Pages (from-to)	140-5
Number of pages	6
Journal	Diabetes Research and Clinical Practice
Volume	86
Issue number	2
DOIs	https://doi.org/10.1016/j.diabres.2009.08.013
Publication status	Published - Nov 2009
Externally published	Yes

Keywords

Age of Onset
Aged
Blood Pressure
Cardiovascular Diseases/genetics
Cohort Studies
Diabetes Mellitus, Type 2/genetics
Diabetic Angiopathies/genetics
Female
Follow-Up Studies
Genetic Variation
Genotype
Glomerular Filtration Rate
Glycated Hemoglobin A/metabolism
Humans
Male
Middle Aged
Outpatients
Receptors, CCR5/genetics
Survivors/statistics & numerical data
Treatment Outcome

Access to Document

10.1016/j.diabres.2009.08.013

Cite this

@article{5c1bb7b29ac448b2a670268cba87e235,

title = "CCR5Delta32 genotype is associated with outcome in type 2 diabetes mellitus",

abstract = "AIMS: To test whether the genetic variant CCR5Delta32 in the CC-chemokine receptor 5, which is known to lead to CCR5 deficiency, is associated with mortality in type 2 diabetes patients.METHODS: We examined the effect of presence or absence of the CCR5Delta32 on overall and cardiovascular mortality risk in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) cohort, a type 2 diabetes patient cohort.RESULTS: We studied 756 patients with a mean duration of follow-up of 5.4 (+/- 1.4) years. 194 patients died during follow up of which 83 were cardiovascular deaths. 144 subjects (19%) carried the CCR5Delta32 deletion. CCR5Delta32 carriers had an adjusted hazard ratio of 0.62 (95%CI: 0.40-0.96; p=0.03) for all-cause mortality and 0.63 (95%CI: 0.33-1.19; p=0.16) for cardiovascular mortality.CONCLUSIONS: The presence of CCR5Delta32 is associated with better survival in type 2 diabetes patients. These data suggest that it is worthwhile to explore the protective potential of pharmacological blockade of CCR5 in type 2 diabetic patients.",

keywords = "Age of Onset, Aged, Blood Pressure, Cardiovascular Diseases/genetics, Cohort Studies, Diabetes Mellitus, Type 2/genetics, Diabetic Angiopathies/genetics, Female, Follow-Up Studies, Genetic Variation, Genotype, Glomerular Filtration Rate, Glycated Hemoglobin A/metabolism, Humans, Male, Middle Aged, Outpatients, Receptors, CCR5/genetics, Survivors/statistics & numerical data, Treatment Outcome",

author = "Muntinghe, {Friso L H} and Sascha Gross and Bakker, {Stephan J L} and Landman, {Gijs W D} and {van der Harst}, Pim and Bilo, {Henk J G} and Gerjan Navis and Zuurman, {Mike W}",

year = "2009",

month = nov,

doi = "10.1016/j.diabres.2009.08.013",

language = "English",

volume = "86",

pages = "140--5",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - CCR5Delta32 genotype is associated with outcome in type 2 diabetes mellitus

AU - Muntinghe, Friso L H

AU - Gross, Sascha

AU - Bakker, Stephan J L

AU - Landman, Gijs W D

AU - van der Harst, Pim

AU - Bilo, Henk J G

AU - Navis, Gerjan

AU - Zuurman, Mike W

PY - 2009/11

Y1 - 2009/11

N2 - AIMS: To test whether the genetic variant CCR5Delta32 in the CC-chemokine receptor 5, which is known to lead to CCR5 deficiency, is associated with mortality in type 2 diabetes patients.METHODS: We examined the effect of presence or absence of the CCR5Delta32 on overall and cardiovascular mortality risk in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) cohort, a type 2 diabetes patient cohort.RESULTS: We studied 756 patients with a mean duration of follow-up of 5.4 (+/- 1.4) years. 194 patients died during follow up of which 83 were cardiovascular deaths. 144 subjects (19%) carried the CCR5Delta32 deletion. CCR5Delta32 carriers had an adjusted hazard ratio of 0.62 (95%CI: 0.40-0.96; p=0.03) for all-cause mortality and 0.63 (95%CI: 0.33-1.19; p=0.16) for cardiovascular mortality.CONCLUSIONS: The presence of CCR5Delta32 is associated with better survival in type 2 diabetes patients. These data suggest that it is worthwhile to explore the protective potential of pharmacological blockade of CCR5 in type 2 diabetic patients.

AB - AIMS: To test whether the genetic variant CCR5Delta32 in the CC-chemokine receptor 5, which is known to lead to CCR5 deficiency, is associated with mortality in type 2 diabetes patients.METHODS: We examined the effect of presence or absence of the CCR5Delta32 on overall and cardiovascular mortality risk in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) cohort, a type 2 diabetes patient cohort.RESULTS: We studied 756 patients with a mean duration of follow-up of 5.4 (+/- 1.4) years. 194 patients died during follow up of which 83 were cardiovascular deaths. 144 subjects (19%) carried the CCR5Delta32 deletion. CCR5Delta32 carriers had an adjusted hazard ratio of 0.62 (95%CI: 0.40-0.96; p=0.03) for all-cause mortality and 0.63 (95%CI: 0.33-1.19; p=0.16) for cardiovascular mortality.CONCLUSIONS: The presence of CCR5Delta32 is associated with better survival in type 2 diabetes patients. These data suggest that it is worthwhile to explore the protective potential of pharmacological blockade of CCR5 in type 2 diabetic patients.

KW - Age of Onset

KW - Aged

KW - Blood Pressure

KW - Cardiovascular Diseases/genetics

KW - Cohort Studies

KW - Diabetes Mellitus, Type 2/genetics

KW - Diabetic Angiopathies/genetics

KW - Female

KW - Follow-Up Studies

KW - Genetic Variation

KW - Genotype

KW - Glomerular Filtration Rate

KW - Glycated Hemoglobin A/metabolism

KW - Humans

KW - Male

KW - Middle Aged

KW - Outpatients

KW - Receptors, CCR5/genetics

KW - Survivors/statistics & numerical data

KW - Treatment Outcome

U2 - 10.1016/j.diabres.2009.08.013

DO - 10.1016/j.diabres.2009.08.013

M3 - Article

C2 - 19744740

SN - 0168-8227

VL - 86

SP - 140

EP - 145

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

IS - 2

ER -

CCR5Delta32 genotype is associated with outcome in type 2 diabetes mellitus

Abstract

Keywords

Access to Document

Fingerprint

Cite this